PER 0.00% 10.0¢ percheron therapeutics limited

Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-146

  1. 994 Posts.
    lightbulb Created with Sketch. 165
    Yes I agree with what you are saying in regards to the sp action. I for one was more focused on the EMA trials anyway in regards to timelines. The fda was always going to be a longer time frame, I know they were looking at a combination ema and fda this just makes me think the focus will go back on progressing with the ema. Fingers crossed ema are happy with trial design.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.